Objectives of the AMC

As agreed by the AMC Donor Committee, the objectives of the pneumococcal AMC upon which the IWG grounded its deliberations are:

1. To accelerate the development of pneumococcal vaccines that meet developing country needs (e.g. serotype composition and vaccine presentation) as specified in the Target Product Profile (TPP).

2. To bring forward the availability of effective pneumococcal vaccines for developing countries by guaranteeing the initial purchase price, for a limited quantity of the new vaccines, that represents value for money and incentivizes manufacturers to invest in scaling-up production capacity to meet developing country vaccine demand.

3. To accelerate vaccine uptake by ensuring predictable vaccine pricing for countries and manufacturers, including binding commitments by participating companies to supply the vaccines at low, long-term and sustainable prices after the AMC finances are depleted.

4. To pilot test the effectiveness of the AMC mechanism as an incentive for needed vaccines and to learn lessons for possible future AMCs.

Related Information

Supporters

Objectives of the Pilot AMC